Davis Polk advised the underwriters in connection with an SEC-registered offering by AMAG Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible senior notes due 2022.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families it serves.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Jeannette K. Safi. The equity derivatives team included partner Mark M. Mendez and associates Barry J. Gewolb and Hanbing Zhang. The tax team included partner Michael Farber. Associate Paul S. Lee provided intellectual property and technology advice. Counsel Ann Becchina and associate Timothy John Durbin provided ERISA advice. All members of the Davis Polk team are based in the New York Office. 

Copy link to share post